BH-3012

N/A

Report date: 2025/01/26 16:20:25

Base Information

Drug NameBH-3012
Drug Alias NamePD-L1/CD47 bispecific antibody (Beijing Hanmi)dual PD-L1 checkpoint inhibitor/CD47 checkpoint inhibitor (Beijing Hanmi)BH-29xxBH-3012
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1Cluster of differentiation 47
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Hanmi Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Hanmi Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A